Modality
siRNA
MOA
PD-1i
Target
IL-17A
Pathway
PI3K/AKT
OCDMigraine
Development Pipeline
Preclinical
~Sep 2022
→ ~Dec 2023
Phase 1
Mar 2024
→ Jan 2030
Phase 1Current
NCT05338195
1,411 pts·Migraine
2024-03→2029-11·Completed
NCT04668290
2,323 pts·OCD
2024-08→2030-01·Completed
3,734 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2029-11-083.6y awayPh2 Data· Migraine
2030-01-033.8y awayPh2 Data· OCD
Trial Timeline
Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030
P1/2
Complet…
P1/2
Complet…
Catalysts
Ph2 Data
2029-11-08 · 3.6y away
Migraine
Ph2 Data
2030-01-03 · 3.8y away
OCD
Completed|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05338195 | Phase 1/2 | Migraine | Completed | 1411 | PANSS |
| NCT04668290 | Phase 1/2 | OCD | Completed | 2323 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| GSK-7987 | GSK | Phase 3 | MDM2 | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| Nirabrutinib | BioNTech | Phase 2/3 | CDK2 | |
| Cevinaritide | Genmab | Phase 2/3 | DLL3 | |
| RVM-7089 | Revolution Medicines | Phase 3 | IL-17A | |
| Adagrarapivir | Ideaya Bio | Phase 1/2 | IL-17A | |
| ZYM-2450 | Zymeworks | Phase 2 | GLP-1R | |
| Polazanubrutinib | Tango Ther | Phase 1 | IL-17A |